fruquintinib,regorafenib
hutchmed,bayer
['colorectal', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', ' rego ', 'rectal', 'crcsm', 'hutchmed']
#esmo22 phase 3 global fresco os of 2.6m and pfs of 1.9m regardless of prior tas-102 +/- rego new option for our #crc patients. i am so honored to help lead this trial w/ #colorectalcancer #cancer #cancerresearch #crcsm 
Co-Director/Co-Leader GI Oncology Research; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee; and Director for Strategic Relations